Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced a $7 million underwritten offering of 1 million common shares at $7 each to a single investor. The funds will support general corporate expenses and advance the development of their lead drug candidate CNM-Au8®, including NDA preparation, ongoing and future clinical trials, manufacturing expansion, and early-stage research. The offering is expected to close around May 6, 2026. This capital raise is crucial for Clene's efforts to bring new treatments for diseases like ALS and multiple sclerosis to market.
Eramet has appointed Simon Henochsberg as its new Group Chief Financial Officer and member of the Executive Committee, effective May 26, 2026. Henochsberg, who previously served as Vice President of Group Strategy and co-Chief Financial Officer, brin...
Funnel has introduced Digital Measurement, a new marketing mix modeling (MMM) software that integrates MMM, Multi-Touch Attribution (MTA), and ad platform signals into one calibrated system. This approach addresses the limitations of relying on a sin...
Zealand Pharma held an Extraordinary General Meeting on May 26, 2026, where all proposals were approved, including the election of Camilla Sylvest to the Board of Directors. The board now consists of seven shareholder-elected members and four employe...
Nvidia has been a top AI investment as demand for AI chips surged, but the next wave of IPOs from major AI customers like SpaceX, OpenAI, and Anthropic could shift investor focus. These companies, while not competitors in hardware, may compete for in...
Salazar Resources announced a new copper-gold porphyry system discovery at its 100%-owned Monja Project in southern Ecuador, featuring high-grade surface samples. This discovery comes as global copper prices hit record highs due to supply deficits, i...
